e-learning
resources
Stockholm 2002
Monday 16.09.2002
Cystic fibrosis: new science, new epidemiology, new problems
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
G. Pisi, G. Grzincich, C. Spaggiari, G. Attanasi, R. Marvasi, A. Battistini (Parma, Italy)
Source:
Annual Congress 2002 - Cystic fibrosis: new science, new epidemiology, new problems
Session:
Cystic fibrosis: new science, new epidemiology, new problems
Session type:
Thematic Poster Session
Number:
2125
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Pisi, G. Grzincich, C. Spaggiari, G. Attanasi, R. Marvasi, A. Battistini (Parma, Italy). Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients. Eur Respir J 2002; 20: Suppl. 38, 2125
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Related content which might interest you:
Antibiotic treatment of cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 188-202
Year: 2014
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021
The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013
The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Pulmonary hypertension in cystic fibrosis patients
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
Lung clearance index improves with treatment of an exacerbation in cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Year: 2007
Evaluation of functional capacity and pulmonary functions during acute pulmonary exacerbation in children with cystic fibrosis
Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases
Year: 2020
Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017
Year: 2018
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020
Year: 2021
Home intravenous antibiotic treatments in cystic fibrosis adult patients
Source: Eur Respir J 2002; 20: Suppl. 38, 158s
Year: 2002
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations
Source: Eur Respir J 2015; 46: 1055-1064
Year: 2015
Long-term course of lung clearance index among patients with cystic fibrosis
Source: Virtual Congress 2020 – Respiratory physiology and sleep: new approaches to diagnosis and treatment
Year: 2020
Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function
Source: International Congress 2016 – Cystic fibrosis: monitoring and management
Year: 2016
Changes in pulmonary function tests following antibiotics in infants with pulmonary exacerbation of cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment
Year: 2013
Clinical characteristics and pulmonary function in patients with pulmonary fibrosis assessed for lung transplant
Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept